慢性伤口治疗中普遍存在的问题？

首页
病情图文
- 糖尿病足
- 压疮
- 感染伤口
- 造口
- 溃疡
  
  动脉性溃疡
  
  静脉性溃疡
  
  放射性溃疡
- 烧伤
- 创伤
- 少见伤口
- 祛疤止痒
- 皮肤病
医师讲座
名医介绍
专业服务

糖尿病足

压疮

造口

溃疡

烧伤
蔡道章院长

Custom Mod Mega1

主任医师、教授、博导，南方医科大学第三附属医院（广东省骨科医院）院长

中德骨科伤口管理学校校长

广东省骨科研究院运动医学研究所所长

广东省内运动医学专业唯一的博士研究生导师

美国哈弗大学医学院骨科访问学者

专业特长处于省内领先、国内或国际先进水平以上

2018年获得“国之名医卓越建树”荣誉称号

2017年被评为全国卫生计生系统先进工作者、广东省医学领军人才

中国医师协会运动医师分会副会长

STCOT中国部运动医学分会副主任委员

广东省医学会关节外科分会主任委员

广东省医学会运动医学会分会名誉主任委员

独立承担过国家“863”课题，主持过10余项省、部级科研项目

多份专业杂志编委
文献精选
伤口分类

糖尿病足

压疮

感染伤口

造口

溃疡

烧伤

更多关于伤口信息
最新文献

GLP-1 receptor agonists and coronary plaques regression in diabetic patients after acute coronary syndromes 2026-05-16 00:00

Mauro Gitto1,2 · Federica Catapano1,2 · Marco Francone1,2 · Gianluca Mincione1,2 · Vincenzo Scialò1,2 ·Carlo A. Pivato1,2 · Costanza Lisi1,2 · Damiano Regazzoli1,2 · Davide Cao1,2 · Roberta Maria Fiorina1 ·Alessandra Petrelli3,4 · Loredana Bucciarelli4 · Cristian Loretelli3,4 · Gianluigi Condorelli1,2 · Paolo Fiorina3,4,5 · Giulio Stefanini1,2

Received: 4 October 2025 / Accepted: 15 October 2025 / Published online: 4 November 2025 © The Author(s) 2025

Abstract

Background Despite advances in therapeutic strategies a significant proportion of acute coronary syndrome (ACS) patients experience early coronary artery disease (CAD) progression, particularly those with diabetes.

Aim To evaluate CAD progression in diabetic patients treated with glucagon-like peptide 1 receptor agonists (GLP-1Ra) over 1 year after an ACS.

Methods Patients presenting with non–ST-elevation ACS between 2019 and 2022 were enrolled in a prospective registry and underwent serial coronary computed tomography angiography (CCTA) at baseline (after revascularization, during the index hospitalization) and at 1-year follow-up. The primary endpoint was the absolute change (1 year – baseline) in non-culprit lesion plaque burden (ΔPB) on CCTA, with the absolute change in patient percent atheroma volume (ΔPAV) as a key secondary endpoint. A comprehensive lipidomic, metabolomic, and proteomic plasma assessment was also performed in all GLP-1Ra–treated patients and four randomly selected controls.

Results Of 28 diabetic patients, 7 (25%) with 22 coronary plaques were treated with GLP-1Ra, and 21 (75%) with 65 plaques received other antidiabetic agents. In the 1-year observation frame, both ΔPB (-5.8±12.8% vs. -1.1±13.6%, p=0.041) and ΔPAV (-6.1% [-7.3, -1.8] vs. -0.7% [-2.4, 9.8], p=0.039) were significantly lower in GLP-1Ra-treated patients. Total atheroma volume also showed a numerically greater reduction in the GLP-1Ra cohort (0.7 mm³ [-2.5-8.7] vs. 25.0 mm³ [4.8–39.7]), primarily due to a decrease in plaque fibrofatty volume percentage (-2.9±10.1% vs. 1.0±6.8%, p=0.042). Lipi-domic, metabolomic, and proteomic analyses identified reductions in monoacylglycerols and triacylglycerols, increases in diacylglycerols and phosphatidylethanolamine, a shift from carbohydrate metabolism toward lipid metabolism and hormone regulation, and differential expression of proteins involved in complement activation, endothelial function, and cytoskeletal organization in GLP-1Ra–treated patients compared with controls.

Conclusions In diabetic patients with ACS, GLP-1Ra therapy was associated with a significant regression in coronary plaque burden at 1 year, supported by favorable lipidomic, metabolomic, and proteomic changes. These findings suggest a potential role for GLP-1Ra in modifying atherosclerosis progression beyond glycemic control.

Keywords GLP-1 receptor agonists · Diabetes mellitus · Coronary artery disease · Acute coronary syndrome · Plaque regression

Anxiety, social responsiveness, and grit among patients with KCNJ11- related neonatal diabetes compared to unaffected siblings 2026-05-15 00:00

Jui M. Desai1 · Lisa R. Letourneau-Freiberg1 · Kristen E. Wroblewski2 · Megan N. Scott3 · Michael E. Msall4 · Siri Atma W. Greeley1,4

Received: 27 February 2025 / Accepted: 4 October 2025 / Published online: 27 January 2026 © The Author(s) 2026

Abstract

Aims Neonatal diabetes mellitus (NDM) occurs before 6–12 months of age and is commonly caused by activating mutations in KCNJ11 (KCNJ11-NDM) or ABCC8. Because of brain expression of these mutant ATP-dependent potassium channels, a spectrum of divergent neurodevelopmental difficulties have been described, including developmental delay, epilepsy, and neonatal diabetes (DEND). However, information on anxiety, social responsiveness, and grit is limited.

Methods Individuals with KCNJ11-NDM (N= 12) and their unaffected siblings (N=12) were recruited through the Uni-versity of Chicago Monogenic Diabetes Registry and participants or their parent/caregiver completedthe Screen for Adult/ Child Anxiety Related Disorder (SCAARED/SCARED), the Social Responsiveness Scale, Second Edition (SRS-2), and the Grit Scale.

Results Mean SRS-2 scores were significantly different between KCNJ11-NDM and sibling controls (P= <0.001 ), with 7/10 affected participants, and 0 /11 siblings, having scores suggestive of autism spectrum disorder (ASD). Differences in anxiety (P=0.69) and grit (P=0.46) were not significant when compared to sibling controls; however, 58% (7/12) of KCNJ11-NDM participants and 40% (4/10) of sibling controls had scores indicating an anxiety disorder by either self- or parent-report.

Conclusions Our results agree with previous studies suggesting significant difficulties with social functioning in KCNJ11- NDM, with 7/10 participants having scores suggestive of ASD, strongly reinforcing the need for early neurodevelopmental screening to allow for prompt support. Our report adds to the knowledge of this population in finding robust grit scores but with a high level of anxiety in both KCNJ11-NDM and unaffected siblings. Although families affected by KCNJ11-NDM may have a high risk of anxiety disorders, it is encouraging that affected and unaffected children exhibit robust self-resiliency that will help support functioning through the challenges of life. Study of additional individuals will help to clarify specific challenges, long-term outcomes, and best approaches for monitoring and support.

Keywords Diabetes mellitus · Potassium channels · Brain · Anxiety · Resilience · Genetics
互动快递

慢性伤口治疗中普遍存在的问题？

字号 + –

12 10月 2019

1
2
3
4
5

Author : 伤口世界

慢性伤口治疗中普遍存在的问题？

原创：卢魁

慢性伤口治疗中普遍是什么问题困扰着患者呢？

问题一：悲观思想，认为患了不治之症
事实上，精神压力和疾病之间，存在着一条明显的纽带。对疾病切勿忧虑恐惧，悲观失望，郁郁寡欢，闷闷不乐，要学会自我克制、自我调节，要心胸宽广，豁达大度，树立战胜疾病的信念，要有毅力和勇气。
问题二:
轻信广告和传言，相信“神药”
慢性伤口是一种长期慢性疾病，其中很多疾病都是没有办法完全根治的，因此必须要有长期和疾病做斗争的思想认识。切勿相信广告所说的秘方、神药，以免上当受骗，耽误病情。
问题三：
为什么症状控制后仍需要长期观察预防复发？
到目前为止，慢性伤口大部分尚不能根治，需要长期治疗让伤口愈合。症状减轻仅意味着病情得到控制，并未完全治愈。体内的病变可能并没有真正停止，停药后或受到外界刺激仍会复发。只有改变生活习惯、合理功能锻炼、合理使用控制病情的药物(慢作用药物)，才能减缓或阻止上述过程的进展。

5222 Views

伤口世界

Latest from 伤口世界

学术会议

2019广东省医疗行业协会伤口管理分会年会

扫一扫了解详情:

2019年6月15日中国广州
主办单位：广东省医疗行业协会伤口管理分会

伤口世界提示

任何关于疾病的建议都不能替代执业医师的面对面诊断。所有门诊时间仅供参考，最终以医院当日公布为准。

网友、医生言论仅代表其个人观点，不代表本站同意其说法，请谨慎参阅，本站不承担由此引起的法律责任。